TABLE 1.
Patient characteristics at the start of second line therapy
| n/median | % [IQR] | |
|---|---|---|
| Age (years) | 67 | [60, 70] |
| Sex | ||
| Male | 32 | (54.2) |
| Primary tumor location | ||
| Head | 23 | (39.0) |
| Disease status | ||
| Locally advance | 2 | (3.4) |
| Metastatic | 57 | (96.6) |
| Metastatic disease | ||
| Liver | 44 | (74.6) |
| Peritoneal dissemination | 21 | (35.6) |
| Lung | 10 | (17.0) |
| ECOG PS | ||
| 0 | 28 | (48.3) |
| 1 | 22 | (37.9) |
| 2 | 8 | (13.8) |
| Best effect of the first line therapy | ||
| Partial response | 20 | (33.9) |
| Stable disease | 24 | (40.7) |
| Progressive disease | 15 | (24.4) |
| RDI of the first line therapy (%) | 76 | [59, 93] |
| PFS of the first line therapy (months) | 5.25 | [2.92, 7.30] |
| Body composition at the start of second line | ||
| BMI | 21.00 | [19.70, 22.50] |
| SMI (cm2/ m2) | 39.38 | [35.06, 44.07] |
| SFA (cm2) | 7869 | [3547.00, 10,757.50] |
| VFA (cm2) | 5597 | [3524.50, 10,618.50] |
| Change rate of Body composition during the first line therapy | ||
| BMI (%) | –2.30 | [–7.93, 1.92] |
| SMI (%) | 0.19 | [–7.53, 6.48] |
| SFA (%) | –4.17 | [–35.91, 22.16] |
| VFA (%) | –18.39 | [–37.91, 14.37] |
| Second‐line regimen | ||
| mFFX | 29 | (49.2) |
| S‐1 | 30 | (50.8) |
Abbreviations: BMI, body mass index; mFFX, modified FOLFIRINOX; PFS, progression‐free survival; PS, performance status; RDI, relative dose intensity; SFA, subcutaneous fat area; SMI, skeletal muscle index; VFA, visceral fat area.